Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline